Introduction

This page provides a comprehensive analysis of the known insider trading history of Mark T Giles. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Mark T Giles has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:DFFN / Diffusion Pharmaceuticals Inc Director 83,300
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Mark T Giles. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Mark T Giles as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2021-07-06 2021-07-01 4 DFFN Diffusion Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 83,300 83,300
2020-06-18 2020-06-17 4 DFFN Diffusion Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 61,300 61,300
2019-08-06 2019-06-13 4/A DFFN Diffusion Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 19,200 19,200
2019-07-19 2019-06-13 4 DFFN Diffusion Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 13,100 13,100
2018-06-18 2018-06-14 4 DFFN Diffusion Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 40,000 40,000
2018-01-04 2018-01-02 4 DFFN Diffusion Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 25,000 25,000
2017-06-16 2017-06-15 4 DFFN Diffusion Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 23,900 23,900
2016-12-28 2016-12-28 4 DFFN Diffusion Pharmaceuticals Inc.
Common Stock
P - Purchase 290,580 802,689 56.74
2016-12-28 2016-12-27 4 DFFN Diffusion Pharmaceuticals Inc.
Common Stock
J - Other -290,580 0 -100.00
2016-12-16 2016-12-15 4 DFFN Diffusion Pharmaceuticals Inc.
Common Stock
P - Purchase 512,109 512,109
2016-12-16 2016-12-14 4 DFFN Diffusion Pharmaceuticals Inc.
Common Stock
J - Other -339,055 290,580 -53.85
2016-12-13 2016-12-08 4 DFFN Diffusion Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 14,000 14,000
2016-07-25 2016-07-21 4 DFFN Diffusion Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 58,473 58,473
2016-01-12 2016-01-08 4 RESX RestorGenex Corp
Stock Option (Right to Buy)
A - Award 365,265 365,265
2016-01-12 2016-01-08 4 RESX RestorGenex Corp
Stock Option (Right to Buy)
A - Award 182,632 182,632
2016-01-12 2016-01-08 4 RESX RestorGenex Corp
Stock Option (Right to Buy)
A - Award 182,632 182,632
2016-01-12 2016-01-08 4 RESX RestorGenex Corp
Stock Option (Right to Buy)
A - Award 91,316 91,316
2016-01-12 2016-01-08 4 RESX RestorGenex Corp
Stock Option (Right to Buy)
A - Award 98,621 98,621
2016-01-12 2016-01-08 4 RESX RestorGenex Corp
Common Stock
A - Award 6,296,346 6,296,346
2016-01-12 2016-01-08 4 RESX RestorGenex Corp
Common Stock
A - Award 44,069 44,069
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)